Amylin lead director accused of mischaracterizing Icahn's comments

By Lisa Kerner

Charlotte, N.C., April 20 - Amylin Pharmaceuticals, Inc. shareholder Carl C. Icahn said lead director James N. Wilson, in a Monday letter to Icahn, "misstated and mischaracterized" conversations between Icahn, Wilson and Amylin chairman Joseph Cook that took place over the weekend.

Icahn said he plans to issue a letter shortly to Wilson and Cook discussing the details of the conversations.

Wilson's letter to Icahn was included in a schedule 14A filed with the Securities and Exchange Commission on Monday.

According to Wilson, Icahn:

• Suggested that Amylin be promptly sold to Eli Lilly & Co.;

• Stated he would implement drastic cost cuts of an additional 30% beyond the 16% Amylin achieved in the first quarter of 2009; and

• Asked "Who is Dan Bradbury?"

Bradbury is the San Diego biopharmaceutical company's president and chief executive officer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.